Full-Time

Mechanical Engineer 2

QuidelOrtho

QuidelOrtho

1,001-5,000 employees

Develops, produces, and markets diagnostic tests

Compensation Overview

$78k - $90k/yr

+ Bonus

No H1B Sponsorship

Rochester, NY, USA

In Person

On-site in Rochester, New York; up to 10% travel (domestic and international).

Bachelor's, Master's

Category
Mechanical Engineering (1)

Get referred to QuidelOrtho

See people who can refer or advise you

Requirements
  • Bachelor's degree in mechanical engineering with 3-5 years of experience, Master's degree with at least 1 year of experience
  • Strong verbal and written communication skills, with the ability to convey complex technical information to diverse audiences and influence cross functional parties
  • Ability to work effectively in a collaborative, cross-functional team environment
  • Strong mechanical aptitude, analytical abilities, troubleshooting, and problem-solving skills, with a focus on delivering innovative solutions
  • Must have strong customer focus to ensure that the experience delivered by the product is consistent with expectations
  • Results orientation: Must be capable of making commitments, setting priorities, and delivering results in time and on budget in a highly regulated environment
  • Situational Adaptability: Sees ahead clearly; can anticipate future concerns
  • Develops and maintains effective cross functional relationships and is capable of quickly earning trust and respect
  • Must have the ability to travel 10% both domestic and international
  • This position is not currently eligible for visa sponsorship
Responsibilities
  • Contribute to and/or lead design and analysis efforts on multiple sustaining engineering projects
  • Drive the design change process from conception through implementation
  • Collaborate across multiple functions
  • Collaborate with part/assembly suppliers
  • Review and/or update Design History File Documents including Design Specifications, Subsystem Requirements Documents, FMECA Analysis and Verification Test Plans/Reports
  • Support other teams by participating in design reviews, suggesting improvements, and providing feedback as an R&D representative
  • Develop and execute test plans, protocols, and reports for design changes from early development feasibility through formal verification
  • Participate and/or lead root cause investigations and recommend corrective actions in the field of mechanical engineering
  • Perform other work-related duties as assigned
Desired Qualifications
  • Familiarity with working in a regulated environment i.e. medical device, aerospace, automative
  • Familiarity with medical device regulations and standards (e.g., FDA, ISO 13485, etc.)
  • Familiarity with Clinical Chemistry and/or Immunohematology in vitro diagnostic instruments
  • Design for Manufacturability and Serviceability experience

QuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1937

Get referred to QuidelOrtho

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Micah Young became CFO on July 6, 2026, sharpening cash and capital discipline.
  • Brian Blaser said non-China labs and immunohematology should grow 3% to 5% second half.
  • QuidelOrtho still guides $2.52 billion to $2.60 billion revenue for 2026, preserving scale.

What critics are saying

  • China revenue fell 18.7% in Q2 2026 after pricing-guideline changes hit ordering.
  • Management withdrew 2026 free cash flow guidance after using $143.6 million operating cash.
  • Federal securities class actions over COVID-19 tests and Savanna RVP4 disclosures stay ongoing.

What makes QuidelOrtho unique

  • QuidelOrtho spans labs, point-of-care, immunohematology, and transfusion medicine across one platform.
  • Q2 2026 labs revenue reached $382.9 million, and point-of-care grew 16%.
  • Outside China, Q2 2026 revenue rose 6%, showing portfolio resilience beyond one market.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance Program

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

6%
PR Newswire
Aug 6th, 2026
QuidelOrtho cuts 2026 guidance as China pricing changes and respiratory slowdown weigh on $631M Q2 revenue

QuidelOrtho reported second quarter 2026 revenue of $631 million, up 3% year-over-year. Excluding China, total revenue grew 6%. The diagnostics solutions provider saw Labs revenue reach $383 million and Point of Care revenue hit $108 million, growing 16%. The company reported a GAAP net loss of $93 million and adjusted EBITDA of $129 million. However, challenges in China related to proposed in vitro diagnostics pricing guidelines impacted performance. QuidelOrtho reduced its full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion previously. Adjusted EBITDA guidance was lowered to $540-$560 million from $615-$630 million. The company withdrew its free cash flow guidance as it works through working capital impacts. Chief executive Brian Blaser cited demand headwinds in China and a softer global respiratory environment as reasons for the revision.

MarketBeat
Jul 29th, 2026
QuidelOrtho Corporation (NASDAQ:QDEL) receives consensus rating of "Reduce" from analysts.

QuidelOrtho Corporation (NASDAQ:QDEL) receives consensus rating of "Reduce" from analysts. July 29, 2026 Key points. * Analysts maintain a cautious view of QuidelOrtho: six firms assign the stock a consensus "Reduce" rating, including two sells and four holds. The average 12-month price target is $13.63, below the reported opening price of $16.67. * QuidelOrtho's latest quarterly results missed expectations, with a $0.04 loss per share versus the anticipated $0.37 profit and revenue of $619.8 million versus $665.2 million expected. Revenue declined 10.5% year over year, while the company reported a negative 45.57% net margin. * Institutional ownership remains high at 99%: several hedge funds increased their positions, including Segall Bryant & Hamill, which added 29.2% to its holdings, and GAMMA Investing, which raised its stake by 67.7%. * MarketBeat previews top five stocks to own in August. Shares of QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) have been given an average rating of "Reduce" by the six ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $13.6250. QDEL has been the topic of several research analyst reports. Zacks Research upgraded shares of QuidelOrtho from a "strong sell" rating to a "hold" rating in a research report on Monday, June 15th. UBS Group reiterated a "neutral" rating and issued a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of QuidelOrtho in a report on Friday, July 17th. Jefferies Financial Group restated a "hold" rating on shares of QuidelOrtho in a research report on Monday, June 29th. Finally, Citigroup increased their target price on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a "neutral" rating in a report on Wednesday, July 8th. QuidelOrtho stock down 1.0%. QDEL opened at $16.67 on Wednesday. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80. The business has a 50 day simple moving average of $15.10 and a 200-day simple moving average of $18.41. The stock has a market capitalization of $1.14 billion, a P/E ratio of -0.94 and a beta of 0.69. QuidelOrtho has a 12 month low of $9.92 and a 12 month high of $35.58. QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.41). The business had revenue of $619.80 million during the quarter, compared to analysts' expectations of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm's quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, equities analysts anticipate that QuidelOrtho will post 1.87 earnings per share for the current fiscal year. Hedge funds weigh in on QuidelOrtho. Several hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in QuidelOrtho by 67.7% during the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company's stock worth $38,000 after purchasing an additional 882 shares during the last quarter. Moody National Bank Trust Division boosted its position in QuidelOrtho by 1.1% during the second quarter. Moody National Bank Trust Division now owns 70,748 shares of the company's stock worth $1,239,000 after purchasing an additional 789 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in QuidelOrtho by 29.2% in the first quarter. Segall Bryant & Hamill LLC now owns 1,543,410 shares of the company's stock valued at $25,358,000 after purchasing an additional 348,549 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in QuidelOrtho in the first quarter valued at $1,937,000. Finally, Amundi increased its position in shares of QuidelOrtho by 50.0% in the first quarter. Amundi now owns 20,989 shares of the company's stock valued at $345,000 after buying an additional 6,996 shares in the last quarter. 99.00% of the stock is owned by hedge funds and other institutional investors. About QuidelOrtho. QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks. Discover more AI Infrastructure Stocks The company's product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider QuidelOrtho, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list. While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Yahoo Finance
Jul 8th, 2026
QuidelOrtho posts weakest Q1 among healthcare equipment stocks with revenues down 10.5% to $619.8M

QuidelOrtho reported first-quarter revenues of $619.8 million, down 10.5% year on year and missing analysts' expectations by 7.3%. The company, formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, develops diagnostic testing solutions for healthcare providers. Chief executive Brian Blaser attributed the results to a weaker respiratory season and business disruption in China and the Middle East. Despite the softer quarter and a significant miss on full-year EPS guidance, the stock has risen 45.7% since reporting. Across the healthcare equipment and supplies sector, 37 tracked stocks delivered satisfactory Q1 results, beating revenue estimates by 2.3% on average. However, next quarter's revenue guidance came in 1.3% below expectations.

Yahoo Finance
Jun 30th, 2026
QuidelOrtho exits Russell growth indexes and appoints ex-Masimo CFO amid losses

QuidelOrtho Corporation was removed from several Russell growth indices in late June 2026, including the Russell 3000 Growth and 2000 Growth, whilst appointing former Masimo finance chief Micah Young as chief financial officer, effective 6 July 2026. The company recently lowered its 2026 revenue guidance to $2.7 billion to $2.75 billion and remains unprofitable. Young's track record in finance and capital allocation at other medical technology companies may influence QuidelOrtho's approach to cost savings and balance sheet management. The index removal could add short-term share price volatility but doesn't directly affect the company's core challenges: stabilising revenues, restoring margins, and managing continued losses with a limited cash runway. Some analysts project revenue could reach $3.1 billion with earnings near $369.3 million, though these forecasts may be reassessed following recent developments.

PR Newswire
Jun 23rd, 2026
QuidelOrtho names Micah Young as CFO, bringing two decades of medtech finance leadership

QuidelOrtho Corporation has appointed Micah Young as chief financial officer, effective 6 July 2026. Young will succeed Joseph Busky, who previously announced his retirement and will serve in an advisory role during the transition. Young most recently served as executive vice president and CFO of Masimo Corporation, joining in 2017. He previously held senior finance roles at NuVasive and Zimmer Holdings, and began his career at Deloitte & Touche. He holds a Bachelor of Science in Accounting and Criminal Justice from Indiana Wesleyan University. QuidelOrtho, a Nasdaq-listed diagnostic solutions provider, said Young's experience improving financial performance and driving disciplined execution will support the company's priorities to enhance profitability and cash generation.